ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies - Join Clinical Trial NCTNCT02362035
How to Join This Clinical Trial - NCTNCT02362035
Learn how to participate in this PHASE1, PHASE2 trial studying an investigational therapy for Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome, Mantle Cell Lymphoma (MCL), Indolent Non Hodgkin Lymphoma, Waldenström Macroglobulinemia, Multiple Myeloma, Hodgkin Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphomas, Mediastinal Large B Cell Lymphoma, Hairy Cell Leukemia. Current status: ACTIVE_NOT_RECRUITING.
Am I Eligible for This Clinical Trial?
This clinical research study is looking for participants with Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome, Mantle Cell Lymphoma (MCL), Indolent Non Hodgkin Lymphoma, Waldenström Macroglobulinemia, Multiple Myeloma, Hodgkin Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphomas, Mediastinal Large B Cell Lymphoma, Hairy Cell Leukemia. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.
- Condition Being Studied
- Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome, Mantle Cell Lymphoma (MCL), Indolent Non Hodgkin Lymphoma, Waldenström Macroglobulinemia, Multiple Myeloma, Hodgkin Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphomas, Mediastinal Large B Cell Lymphoma, Hairy Cell Leukemia
- Treatment Being Tested
- Investigational treatment
- Study Phase
- PHASE1, PHASE2 - Safety and effectiveness study
- Enrollment Status
- ACTIVE_NOT_RECRUITING
- Study Identifier
- NCTNCT02362035 - ClinicalTrials.gov Identifier
- Sponsored By
- Study sponsor
What to Expect as a Participant
Participating in this clinical trial involves:
- Initial screening to determine eligibility
- Regular study visits and health assessments
- Receiving the study treatment or placebo
- Medical monitoring and follow-up care
- Contributing to medical research that may help others
- Potential access to new treatments before they're widely available
Clinical Trial Benefits and Compensation
Participants in this clinical research study may receive:
- Close medical monitoring by healthcare professionals
- Access to potential new treatments
- Compensation for time and travel (varies by study)
- No-cost study-related medical care
- The opportunity to help advance medical knowledge
Where Is This Clinical Trial Located?
This study is enrolling participants at 19 locations. Find a study site near you:
Clinical Research Site
Tucson, Arizona 85704 - United States
Status: Contact for availability
Clinical Research Site
Los Angeles, California 90095 - United States
Status: Contact for availability
Clinical Research Site
Denver, Colorado 80218 - United States
Status: Contact for availability
Clinical Research Site
Washington D.C., District of Columbia 20007 - United States
Status: Contact for availability
Clinical Research Site
Niles, Illinois 60714 - United States
Status: Contact for availability
Clinical Research Site
Boston, Massachusetts 2215 - United States
Status: Contact for availability
Clinical Research Site
Rochester, Minnesota 55905-0001 - United States
Status: Contact for availability
Clinical Research Site
Omaha, Nebraska 68198-7680 - United States
Status: Contact for availability
Clinical Research Site
Columbus, Ohio 43210 - United States
Status: Contact for availability
Clinical Research Site
Greenville, South Carolina 29605 - United States
Status: Contact for availability
And 9 more locations available. Contact us to find the nearest participating site.
How to Enroll in This Study
To learn more about participating in this PHASE1, PHASE2 clinical trial for Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome, Mantle Cell Lymphoma (MCL), Indolent Non Hodgkin Lymphoma, Waldenström Macroglobulinemia, Multiple Myeloma, Hodgkin Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphomas, Mediastinal Large B Cell Lymphoma, Hairy Cell Leukemia:
- Review the eligibility criteria with your healthcare provider
- Contact the study team for a pre-screening interview
- Schedule an in-person screening visit if eligible
- Review and sign the informed consent form
- Begin participation in the clinical trial
Why Choose Quri.ai Study Finder
Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:
- Discover clinical trials before competitors
- Access exclusive contact information
- Track sponsor pipelines and opportunities
- Connect with decision makers directly
- Win more business partnerships